Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy.

Pancreatic cancer is still one of the most fatal neoplastic diseases, and the recurrence occurs in more than 80% of the patients even though radical resection is performed. We experienced a long-term survival case of a patient with peritoneal carcinomatosis from pancreatic cancer maintained by nanoliposomal irinotecan (nal-IRI) in combination with fluorouracil and folinic acid (FF) as third-line chemotherapy. Nal-IRI + FF combination chemotherapy is one of the promising options for the management of intractable recurrent pancreatic cancer.